JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
On Tuesday, BNP Paribas (OTC:BNPQY) Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target to DKK1,500 from DKK2,000. The revision comes as Genmab, a Danish biotechnology company, anticipates a crucial decision from Johnson & Johnson regarding the next generation of its Darzalex drug, referred to as "Darzalex 2.0".
Floch noted that the market’s outlook for Genmab’s shares is cautiously optimistic, given that they are currently trading at a four-year low. The anticipation surrounding the upcoming announcement from J&J has drawn comparisons to the high expectations that preceded the CagriSema readout from Novo Nordisk (NYSE:NVO). According to Floch, the potential outcomes from the upcoming catalyst have a positive skew, with estimates suggesting a possible 20% increase or a 10% decrease in share value. In a more optimistic ’blue-sky scenario,’ the analyst sees the potential for approximately a 60% upside.
However, the analyst also pointed out that the overall visibility into Genmab’s operations is somewhat obscured, with limited news flow beyond the Darzalex updates. This uncertainty has tempered BNP Paribas Exane’s enthusiasm for the stock. The forthcoming Q4 results, scheduled for February 12, are predicted to be unremarkable, which has influenced the firm’s decision to maintain a Neutral stance on the shares despite the upgrade. InvestingPro data reveals that three analysts have recently revised their earnings expectations downward for the upcoming period, though the company maintains robust profitability with a 96.1% gross margin.
Genmab, headquartered in Copenhagen, specializes in the creation of antibody therapeutics for the treatment of cancer. Darzalex, a leading product in its portfolio, has been a significant contributor to the company’s impressive 17.75% revenue growth over the last twelve months, with total revenue reaching $2.96 billion. The market is closely watching for any updates that could impact the company’s future performance and stock valuation. Investors seeking deeper insights can access comprehensive analysis and 11 additional ProTips through InvestingPro’s detailed research report.
In other recent news, Genmab A/S, a Denmark-based biotechnology company, has been active in a variety of developments. The company has reported a capital increase due to the exercise of employee warrants, a move that aligns with its employee incentive plan. Genmab has also granted restricted stock units and warrants to its employees, further promoting workforce retention and alignment with shareholder interests.
In terms of financial performance, Genmab has disclosed its net sales for DARZALEX® (daratumumab) for the year 2024, a significant contributor to the company’s revenue stream. However, the exact sales figures were not disclosed.
H.C. Wainwright, a financial services company, has maintained a Buy rating on Genmab’s shares, following positive results from a Phase 3 MARIPOSA trial conducted by Genmab’s partner, Janssen.
Moreover, Genmab has announced transactions involving its shares by managerial employees and associated persons, providing transparency to its investors in accordance with market regulations.
These recent developments reflect Genmab’s commitment to its employees, financial performance, and adherence to market regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.